We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $214M
1-Year Est. Return 185.33%
This Fund
S&P 500
This Quarter Est. Return
+6.4%
1 Year Est. Return
+185.33%
3 Year Est. Return
+327.48%
5 Year Est. Return
+458.62%
10 Year Est. Return
+1,549.55%
AUM
$189M
AUM Growth
+$9.21M
Cap. Flow
-$665K
Cap. Flow %
-0.35%
Top 10 Hldgs %
92.04%
Holding
44
New
3
Increased
9
Reduced
7
Closed
3

Top Buys

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$980K
2
AAAP
Advanced Accelerator Applications S.A.
AAAP
+$489K
3
XLRN
Acceleron Pharma
XLRN
+$435K
4
PRTK
Paratek Pharmaceuticals, Inc.
PRTK
+$420K
5
CORT icon
Corcept Therapeutics
CORT
+$380K

Top Sells

Rank Stock Value
1
VRML
Vermillion, Inc.
VRML
+$859K
2
WKHS icon
Workhorse Group
WKHS
+$655K
3
MASI
Masimo
MASI
+$643K
4
TSRO
TESARO, Inc.
TSRO
+$550K
5
CTRA
Coterra Energy
CTRA
+$502K

Sector Composition

Rank Sector Weight
1 Healthcare 96.54%
2 Energy 2.18%
3 Consumer Staples 0.56%
4 Miscellaneous 0.29%
5 Industrials 0.27%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CELG
1
DELISTED
Celgene Corp
CELG
$101M 53.25%
775,051
+8,000
+1% +$980K
AXDX
2
DELISTED
Accelerate Diagnostics
AXDX
$59.7M 31.6%
218,380
– –
VRML
3
DELISTED
Vermillion, Inc.
VRML
$4.2M 2.22%
2,282,933
-470,000
-17% -$859K
EQT icon
4
EQT Corp
EQT
$34.4B
$2.48M 1.31%
77,705
– –
BIOL
5
DELISTED
Biolase, Inc.
BIOL
$1.25M 0.66%
103
– –
OVV icon
6
Ovintiv
OVV
$18B
$1.16M 0.62%
26,460
– –
NBIX icon
7
Neurocrine Biosciences
NBIX
$15.9B
$1.16M 0.61%
25,200
– –
OXFD
8
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$1.13M 0.6%
67,303
– –
CORT icon
9
Corcept Therapeutics
CORT
$11.9B
$1.12M 0.59%
95,000
+35,000
+58% +$380K
VNDA icon
10
Vanda Pharmaceuticals
VNDA
$325M
$1.11M 0.59%
68,000
+14,000
+26% +$202K
QDEL icon
11
QuidelOrtho
QDEL
$972M
$1.06M 0.56%
38,975
– –
CFRX
12
DELISTED
ContraFect Corporation
CFRX
$1.05M 0.56%
906
– –
YTEN
13
DELISTED
Yield10 Bioscience, Inc. Common Stock
YTEN
$1.05M 0.56%
236
– –
NXTM
14
DELISTED
NxStage Medical Inc.
NXTM
$857K 0.45%
34,200
+6,000
+21% +$149K
WMGI
15
DELISTED
Wright Medical Group Inc
WMGI
$825K 0.44%
30,000
– –
VCYT icon
16
Veracyte
VCYT
$3.48B
$823K 0.44%
98,767
+4,000
+4% +$32.6K
AAAP
17
DELISTED
Advanced Accelerator Applications S.A.
AAAP
$781K 0.41%
20,000
+13,000
+186% +$489K
MASI
18
DELISTED
Masimo
MASI
$729K 0.39%
8,000
-7,000
-47% -$643K
PRTK
19
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$727K 0.38%
30,150
+19,000
+170% +$420K
TSRO
20
DELISTED
TESARO, Inc.
TSRO
$727K 0.38%
5,200
-3,800
-42% -$550K
CLVS
21
DELISTED
Clovis Oncology, Inc.
CLVS
$655K 0.35%
7,000
-3,000
-30% -$184K
MRK icon
22
Merck
MRK
$373B
$641K 0.34%
10,480
-5,240
-33% -$319K
SIEN
23
DELISTED
Sientra, Inc.
SIEN
$615K 0.33%
6,330
– –
QTNT
24
DELISTED
Quotient Limited Ordinary Shares
QTNT
$587K 0.31%
1,993
+538
+37% +$152K
SITO
25
DELISTED
SITO MOBILE, LTD
SITO
$519K 0.27%
140,000
– –
1
2

Similar funds

EFIC
Eliot Finkel Investment Counsel Beverly Hills, California $214M AUM 62.72% 1-Year Est. Return
CIA
Cladis Investment Advisory Billings, Montana $214M AUM 45.87% 1-Year Est. Return
TCM
Tassel Capital Management Matthews, North Carolina $214M AUM 16.99% 1-Year Est. Return
EFS
Econ Financial Services Harrisburg, Pennsylvania $214M AUM 10.53% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $214M AUM 47.29% 1-Year Est. Return
KWM
Kingsman Wealth Management Pensacola, Florida $214M AUM 46.9% 1-Year Est. Return
FA
Fortis Advisors Wayne, Pennsylvania $214M AUM 41.3% 1-Year Est. Return
MSWM
Mader & Shannon Wealth Management Kansas City, Missouri $214M AUM 23.75% 1-Year Est. Return

Birchview Capital's Q2 2017 Portfolio in Review

As of Q2 2017, Birchview Capital held 44 positions worth $189M, up 5.1% from $180M the previous quarter. Its ten largest holdings account for 92% of the portfolio.

Birchview Capital's Q2 2017 filing shows 3 new, 9 increased, 7 reduced and 3 closed positions. Its largest new stake was Acceleron Pharma: 15,000 shares worth $456K. The largest sale was Vermillion, Inc., an estimated $859K.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier, followed by Energy and Consumer Staples.

  • Birchview Capital's largest Q2 2017 buy was Acceleron Pharma: 15,000 shares worth $456K.
  • Birchview Capital added most to Celgene Corp in Q2 2017, an estimated $980K increase.
  • Birchview Capital's biggest Q2 2017 reduction was Vermillion, Inc., cutting an estimated $859K.
  • Birchview Capital fully exited Coterra Energy in Q2 2017, selling an estimated $502K.
  • Birchview Capital's ten largest holdings make up 92% of its $189M portfolio in Q2 2017.
  • Birchview Capital opened 3 new positions and closed 3 in Q2 2017.
  • Birchview Capital's portfolio value rose 5.1% quarter-over-quarter to $189M.

Based on Birchview Capital's 13F filing for Q2 2017, filed 8 Aug 2017.